Format

Send to

Choose Destination
Antiviral Res. 2013 Nov;100(2):520-34. doi: 10.1016/j.antiviral.2013.08.023. Epub 2013 Sep 4.

Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Author information

1
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105-3678, USA.

Abstract

Many aspects of the biology and epidemiology of influenza B viruses are far less studied than for influenza A viruses, and one of these aspects is efficacy and resistance to the clinically available antiviral drugs, the neuraminidase (NA) inhibitors (NAIs). Acute respiratory infections are one of the leading causes of death in children and adults, and influenza is among the few respiratory infections that can be prevented and treated by vaccination and antiviral treatment. Recent data has suggested that influenza B virus infections are of specific concern to pediatric patients because of the increased risk of severe disease. Treatment of influenza B is a challenging task for the following reasons: This review presents current knowledge of the efficacy of NAIs for influenza B virus and antiviral resistance in clinical, surveillance, and experimental studies.

KEYWORDS:

Antiviral drug resistance; Influenza B virus; Neuraminidase inhibitors; Oseltamivir; Peramivir; Zanamivir

PMID:
24013000
PMCID:
PMC3850058
DOI:
10.1016/j.antiviral.2013.08.023
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center